A non-myeloablative conditioning regimen for allogeneic transplantation with clofarabine, cytarabine, and thymoglobulin [antithymocyte globulin] for myelodysplastic syndrome and acute myeloid leukaemia.
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2013
At a glance
- Drugs Antithymocyte globulin (Primary) ; Clofarabine (Primary) ; Cytarabine (Primary)
- Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
- Focus Therapeutic Use
- 04 Aug 2008 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 05 Feb 2008 New trial record.